Abstract
Introduction: Escherichia coli (E. coli) is one of the leading causes of infections in cancer patients. Antibiotic-resistant E. coli is a major cause of treatment failure in infected cancer patients. This study aims to determine the prevalence and antibiotic susceptibility of E. coli in cancer patients from January 2022 to December 2022 at National Cancer Hospital. Materials and methods: We performed a retrospective review of the culture results of various clinical samples. Results: A total of 283 samples were analyzed to identify E. coli and its antimicrobial profiles. The prevalence of E. coli was 15.9%. The highest isolation rate was obtained from blood samples (35.56%). The highest rate of E. coli resistance was found in ampicillin (95.56%), followed by sulfamethoxazole/trimethoprim (77.76%) and ceftazidime (64.44%). The highest rate of E. coli sensitivity was found in fosfomycin (97.78%), followed by ertapenem, imipenem, meropenem, and amikacin (95.56% each), and nitrofurantoin (93.33%). About 55.56% and 80.0% were ESBL-positive and multidrug-resistant, respectively. Conclusion: E. coli isolates showed high rates of resistance to ampicillin, sulfamethoxazole/trimethoprim, and ceftazidime. Fosfomycin, ertapenem, imipenem, meropenem, amikacin, and nitrofurantoin are considered appropriate for the empirical treatment of E. coli. Regular monitoring of E. coli resistant to antibiotics is recommended.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
